Abstract: An ultrasonic transducer is disclosed, which includes one or a plurality of ultrasonic emitting units. Wavefronts of the ultrasonic waves emitted by the one or the plurality of ultrasonic emitting units are sphere surfaces with uniform radius, and the one or the plurality of ultrasonic emitting units can reflect ultrasound. The one ultrasonic emitting unit is configured to form a spherical resonant cavity, or the plurality of ultrasonic emitting units are configured to form a spherical resonant cavity collectively. An internal cavity of the spherical resonant cavity has a spherical shell shape or a cross-sectional spherical shell shape with a spherical center therein. The ultrasonic waves emitted by the one or the plurality of ultrasonic emitting units are focused on an area in which the spherical center of the spherical resonant cavity is located.

Abstract: The present invention relates to an ultrasound treatment clamp. The ultrasound treatment clamp comprises ultrasound therapy applicators and handles connected to the ultrasound therapy applicators. The handles are clamp-shaped. The two ultrasound therapy applicators with their central axes overlapping each other are mounted face to face on the two clamps of the clamp-shaped handles respectively. A parallel moving mechanism for keeping the two ultrasound therapy applicators in parallel when moving along with clamps is connected between the two clamps. The present invention has a compact structure, a convenient operation, a low treatment cost, a capability of quickly causing a coagulative necrosis of the diseased part. Furthermore, the present invention has an abroad use in treating many kinds of diseases.

Abstract: The present invention is to provide an integrated ultrasound therapy transducer. It includes a piezoelectric transducer to generate therapy ultrasound, a support to support the piezoelectric transducer, a power amplifying module to drive the piezoelectric transducer. Wherein both the power amplifying module and the piezoelectric transducer are installed within the enclosure of the therapy transducer. The advantages of the integrated ultrasound therapy transducer assembly of the present invention include minimizing ultrasound therapy equipment and to decrease its volume and weight; reducing the electromagnetic interference and radiation greatly; and realizing the consistent performances of the ultrasound therapy equipments in mass productions and making the ultrasound therapy equipments have interchangeability.

Abstract: An intelligent tissue mimicking ultrasonic phantom, which is a temperature-sensitive polymer gel having the following acoustic properties and other physical characteristics: acoustic velocity: 1500-1550 m/s; acoustic impedance: (1.50?1.60)×106 Pa·s/m; density: 1.01-1.06 g/cm3; and a denaturation temperature, namely, a Lower Critical Solution Temperature (LCST) or a Volume Phase Transition Temperature at which the volume of the phantom changes, adjustable by changing the ratio of raw materials, around which there is a reversible phase transformation between the opaque phase and the transparent phase. Said gel can be a polymer of isopropylacrylamide (NIPA).

Abstract: The present invention pertains to an ultrasound therapy system and more specifically, to a high-intensity focused ultrasound (HIFU) therapy apparatus guided by image registration and fusion method. The therapy system of the present invention comprises a central control means; an acoustic energy applicator; a mechanical driving and locating means of said acoustic energy applicator; a real-time B-mode ultrasound image guiding device. Further the therapy system of the present invention comprises an immobilization means for body position. By the help of this immobilization means for body position, real-time B-mode ultrasound images can be registered with diagnosis images, and then on the basis of registration, said B-mode ultrasound images are fused with said diagnosis images for guiding said therapy.

Abstract: The present invention is to provide an integrated ultrasound therapy transducer. It includes a piezoelectric transducer to generate therapy ultrasound, a support to support the piezoelectric transducer, a power amplifying module to drive the piezoelectric transducer. Wherein both the power amplifying module and the piezoelectric transducer are installed within the enclosure of the therapy transducer. The advantages of the integrated ultrasound therapy transducer assembly of the present invention include minimizing ultrasound therapy equipment and to decrease its volume and weight; reducing the electromagnetic interference and radiation greatly; and realizing the consistent performances of the ultrasound therapy equipments in mass productions and making the ultrasound therapy equipments have interchangeability.

Abstract: The present invention generally relates to a medical apparatus. More particularly, the present invention relates to an apparatus for delivering a medium to body cavity of mammals including a human, especially to an apparatus for expanding rectum. Specifically, the present invention relates to the field of focused ultrasound treatment with a main purpose to provide an auxiliary device for ultrasound therapy applied to uterine myoma so as to avoid damage by ultrasound after focused within body. Therefore, the present invention provides an apparatus for blocking ultrasound, comprising (1) lead-in means for entering into said body cavity; and (2) accommodation means for containing ultrasound blocking medium, which enwraps the lead-in means outside.

Abstract: This invention provides a MRI guided ultrasound therapy apparatus. It comprises a static field magnet adapted to apply a static magnetic field in an magnetic resonance volume at a predetermined disposition; at least one ultrasound energy applicator adapted to apply energy within an energy application zone at a predetermined disposition; and The mechanical positioning means for moving said ultrasound energy applicator to position the applicator so that the energy application zone intersects said magnetic resonance volume within said region of the subject. In that apparatus, the static field magnet is open at both ends or open at side. The sided open is upward or downward and the mechanical positioning means of this ultrasound energy applicator is close to and is located outside of this sided open. This invention reduces the space limitation for the mechanical positioning means of the ultrasound transducer.

Abstract: The present invention discloses a plasmid enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a nanometer-sized biocompatible solid. The present invention also discloses another plasmid enhancement agent for HIFU treatment, wherein, the enhancement agent comprises a discontinuous phase is comprised of a core material encapsulated by a membrane-forming material, and a continuous phase comprised of aqueous medium; the discontinuous phase is uniformly dispersed in the continuous phase and has a particle size ranging from 10-1000 nm; the amount of the membrane-forming material in the enhancement agent is 0.1-100g/L; and the core material comprises nanometer-sized biocompatible solid selected from the group consisting of magnetic biomaterials, hydroxylapatite, and calcium carbonate, and the amount of the core material in the enhancement agent is 0.1-150 g/L.

Abstract: The apparatus for high-intensity focused ultrasound therapy of the present invention usually comprises a ultrasound transducer, an image acquisition device, a driving unit for driving said ultrasound transducer and mechanical drive means for mechanically driving said ultrasound transducer and image acquisition device together. Additionally, this apparatus for high-intensity focused ultrasound therapy further comprises a signal processing unit connected to image acquisition device for receiving and saving the original images of the target area prior to treatment and for receiving and saving the images of the target area in a certain time during high-intensity focused ultrasound (HIFU) treatment and for evaluating the therapeutic effects according to the images of the target area before and after treatment, and a control unit respectively connected to signal processing unit, driving unit and mechanical driving means.

Abstract: The present invention discloses a fluorocarbon emulsion enhancement agent for HIFU treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a discontinuous phase comprising of a core material encapsulated by a membrane-forming material and a continuous phase comprised of aqueous medium; the discontinuous phase is uniformly dispersed in the continuous phase and the particle size of the discontinuous phase ranges from 0.1-2 ?m; the amount of the membrane-forming material in the enhancement agent is 0.1-100 g/L; the core material is comprised of a liquid that undergoes a liquid-gas phase transition at 38-100° C., and the amount of the core material in the enhancement agent is 5-200 ml/L. The fluorocarbon emulsion enhancement agent for HIFU treatment of the present invention can significantly change the acoustic environment of the target location and can increase acoustic energy deposition at the target location during HIFU treatment.

Abstract: The present invention discloses a particle enhancement agent for high intensity focused ultrasound (HIFU) treatment, which can increase acoustic energy deposition at the target location during HIFU treatment. The enhancement agent comprises a discontinuous phase comprised of a core material encapsulated by a membrane-forming material and a continuous phase comprising of aqueous medium. The discontinuous phase is uniformly dispersed in the continuous phase and the particle size of the discontinuous phase ranges from 0.1-8 ?m; the amount of the membrane-forming material in the enhancement agent is 0.1-100 g/L; the core material is comprised of a liquid that does not undergo a liquid-gas phase transition at 38-100° C., and the amount of core material in the enhancement agent is 5-200 g/L.